
Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …

Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) approve Novartis’ CAR-T …

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …

Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …

Novartis has received approval for its CAR-T treatment of paediatric and young adults with a form of acute lymphoblastic leukaemia …